Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Ani Pharmaceuticals (ANIP) over the last 15 years, with Dec 2024 value amounting to $144.9 million.

  • Ani Pharmaceuticals' Cash & Equivalents rose 81.13% to $262.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $262.6 million, marking a year-over-year increase of 81.13%. This contributed to the annual value of $144.9 million for FY2024, which is 34.49% down from last year.
  • Ani Pharmaceuticals' Cash & Equivalents amounted to $144.9 million in FY2024, which was down 34.49% from $221.1 million recorded in FY2023.
  • Ani Pharmaceuticals' Cash & Equivalents' 5-year high stood at $221.1 million during FY2023, with a 5-year trough of $7.9 million in FY2020.
  • Moreover, its 3-year median value for Cash & Equivalents was $144.9 million (2024), whereas its average is $138.1 million.
  • In the last 5 years, Ani Pharmaceuticals' Cash & Equivalents plummeted by 87.38% in 2020 and then spiked by 1,175.43% in 2021.
  • Over the past 5 years, Ani Pharmaceuticals' Cash & Equivalents (Yearly) stood at $7.9 million in 2020, then skyrocketed by 1,175.43% to $100.3 million in 2021, then slumped by 51.92% to $48.2 million in 2022, then surged by 358.49% to $221.1 million in 2023, then plummeted by 34.49% to $144.9 million in 2024.